MTIM
ZVRA icon

Marathon Trading Investment Management’s Zevra Therapeutics ZVRA Stock Holding History

Marathon Trading Investment Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-33,821
Closed -$295K – 383
2021
Q4 		$295K Buy
+33,821
New +$302K 0.02% 187

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

Marathon Trading Investment Management's ZVRA Position: Q1 2022 in Review

Marathon Trading Investment Management sold out of Zevra Therapeutics (ZVRA) in Q1 2022, closing a stake of 33,821 shares — an estimated $295K sold.

Marathon Trading Investment Management first reported a position in ZVRA in Q4 2021 and held it in 1 quarter. The position peaked at $295K in Q4 2021. 83 funds tracked by Wall St. Rank hold ZVRA as of Q1 2022.

  • Marathon Trading Investment Management reported no remaining Zevra Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Marathon Trading Investment Management sold 33,821 Zevra Therapeutics shares in Q1 2022, an estimated $295K.
  • Marathon Trading Investment Management first reported a position in Zevra Therapeutics in Q4 2021 and held it in 1 quarter.
  • Marathon Trading Investment Management's Zevra Therapeutics position peaked at $295K in Q4 2021.
  • 83 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2022.

Based on Marathon Trading Investment Management's 13F filing for Q1 2022, filed 16 May 2022.